The growth of Benign Prostatic Hyperplasia Treatment Market is driven by the increasing prevalence of benign
prostatic hyperplasia, the rising preference for minimally invasive surgeries,
increasing obesity rate, and investments, funds, and grants for research in the
field of BPH treatment.
The Benign prostatic hyperplasia treatment market is projected to reach USD 14.1
billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to
2026.
Market Segmentation :-
Based on the type, the BPH
treatment market is segmented into drug treatment and surgical treatment. Drug
treatment is the largest and the fastest-growing segment in this market. This
can primarily be attributed to the use of medications as the first line of
treatment among men with mild to moderate symptoms of BPH.
Based on the end user, the
market is segmented into home healthcare and hospitals & clinics. In 2019,
home healthcare accounted for the largest share of this market, as most
patients are prescribed medications over surgery. Patients are also advised to
continue taking medications for a few weeks post-surgery and may even require
catheters for a few days. As a result, the emphasis in his market is skewed
toward home healthcare over hospital care.
Regional Analysis:
On the basis of region, the
benign prostatic hyperplasia treatment market is segmented into North America,
Europe, Asia Pacific, and the Rest of the World. In 2019, North America
commanded the largest share of the benign prostatic hyperplasia treatment
market. The large share of this market segment can be attributed to the rising
geriatric and obese population and the availability of research funding are the
major factors driving the market growth. Initiatives by key players are also
expected to contribute to the market.
Top Key Players: -
The major players operating
in this market are Boston Scientific Corporation (US), Coloplast Group
(Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan),
GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi
Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc.
(Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation
(US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health
Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin
Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies
GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada).
Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ
SE & Co. KG (Germany), and SRS Medical (US).